investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Application of Evolutionary Principles to Maintain Cancer Control (PQ21)
Robert A Gatenby
0 Collaborator(s)
Funding source
National Institutes of Health (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Robert A Gatenby
Moffitt Cancer Center
Tampa, United States
University of South Florida
Tampa, United States
Related projects
Dario Marchetti
Heparanase Mechanisms in Brain-metastatic Breast Cancer
Breast
Dezheng Huo
Epidemiological Study of Breast Cancer in Uganda and Cameroon
Breast
Joe W Gray
Model-based Predictions of Responses RTK Pathway Therapies
Breast
Jeffrey Green
Mechanisms of Tumor Cell Dormancy and Tumor Recurrence
Breast
Joseph Barchi
Carbohydrate Antigen-bearing Nanoparticles for Anti-adhesives and Tumor Vaccines
Breast
Kristina Cotter
Elucidating the Role of Plasma Membrane V-ATPases in Breast Cancer Metastasis
Breast
Pathology
Naoto Ueno
Understanding EGFR's Role in TNBC by an Animal Model
Breast
Jennifer A Pietenpol
p63 and p73 Signaling in Cell Growth and Cancer
Breast
Nathanael S Gray
Developing Selective EphA2 Inhibitors for the Treatment of Cancer
Breast